Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 19 2021 - 08:23AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month January 2021
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name
into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal
executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ¨
No x
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ¨
No x
Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes ¨
No x
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
Item
|
|
Sequential Page Number
|
|
|
|
|
1.
|
Other Relevant Information, dated January 19, 2021
|
|
3
|
|
|
Grifols, S.A.
Parc Empresarial Can Sant Joan
Avda Generalitat nº 152-158
08174 SANT CUGAT DEL VALLES
ESPAÑA
Tel (34) 935 710 500
Fax (34) 935 710 267
|
Grifols, S.A. ("Grifols"),
in accordance with the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative
Royal Decree 4/2015, of 23 October, reports the following
OTHER RELEVANT INFORMATION
GRIFOLS reproduces the text of the Press
Release that it sent to the media regarding the medical trial with a new medicine to treat COVID-19.
"Grifols begins
clinical trial of a new medicine that would provide immediate immunity against COVID-19
|
·
|
The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization
due to the progression of the disease and complementing the vaccine in the early phase after vaccination
|
|
|
|
|
·
|
The medicine, an anti-SARS-CoV-2 immunoglobulin, given subcutaneously, would provide immediate protection after exposure
to the virus and could be used to protect the elderly and healthcare workers. It could also be given to immunocompromised
patients for whom the vaccination isn’t indicated
|
|
|
|
|
·
|
The treatment is based on the Grifols immunoglobulin Gamunex®-C, and contains anti-SARS-COV-2 polyclonal antibodies
from plasma donors who have recovered from COVID-19
|
|
|
|
|
·
|
The clinical trial to evaluate the safety and efficacy of the plasma-derived medicine will have doctors Oriol Mitjà
and Bonaventura Clotet as the principal researchers and is expected to begin in early 2021
|
Barcelona, Spain, January 18, 2021 -
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with
a track record of more than 100 years dedicated to enhancing people’s health and well-being, today announced it will begin
a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C
and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
The new drug would provide immediate post-exposure
protection against the virus and would be especially useful as a complement to the vaccine in the early phase after vaccination.
In addition, it could protect the elderly and healthcare workers as well as immunocompromised patients for whom vaccination isn’t
recommended. It could also help contain outbreaks in places where the vaccination hasn’t begun or is still underway.
Grifols expects this clinical trial, led
by the researchers Oriol Mitjà and Bonaventura Clotet, from Germans Trias i Pujol Hospital in Barcelona, to begin in February
2021, with the possibility of results in the spring.
|
|
Grifols, S.A.
Parc Empresarial Can Sant Joan
Avda Generalitat nº 152-158
08174 SANT CUGAT DEL VALLES
ESPAÑA
Tel (34) 935 710 500
Fax (34) 935 710 267
|
About 800 patients, all asymptomatic but
having tested positive for the virus in a diagnostic test, will participate in the clinical study, receiving subcutaneously Grifols’
immunoglobulin rich with anti-SARS-CoV-2 antibodies.
The Grifols immunoglobulin Gamunex®-C,
whether administered intravenously, intramuscularly or subcutaneously, has proven to be safe and efficacious in the prevention
of diverse infectious diseases in immunocompromised patients and has been used for this for more than 15 years.
According to Dr. Mitjà, “This
treatment based on immunoglobulins would provide a combination of polyclonal antibodies that, compared with monoclonal antibodies,
offers a greater diversity that could improve the degree of protection against the virus.”
Dr. Antonio Páez, Medical Director
at Grifols, underscores that the potential treatment “is easy to refrigerate while its subcutaneous administration facilitates
its distribution and use in any doctor’s office, avoiding hospitalizaton. If the new therapy’s efficacy is confirmed,
it could be administered to people who test positive for the virus through PCR and antigen tests in hospitals and primary care
offices.”
Grifols, a global leader in the production
and distribution of immunoglobulins and hyperimmune immunoglobulins, currently has underway more than 25 research initiatives to
treat different stages of COVID-19, from early exposure to the virus to severe cases requiring hospitalization and intensive care.
In October 2020, Grifols, together with
other companies and various U.S. health agencies, began the clinical trial ITAC (Inpatient Treatment with Anti-Coronavirus Immunoglobulin)
to evaluate the efficacy and safety of the anti-SARS-CoV-2 hyperimmune globulin in hospitalized and serious cases. Results are
expected during the first half of 2021."
In Barcelona, on 19 January 2021
|
|
Nuria Martín Barnés
|
|
Secretary to the Board of Directors
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A.
|
|
|
|
|
|
|
|
By:
|
/s/ David I. Bell
|
|
|
Name:
|
David I. Bell
|
|
|
Title:
|
Authorized Signatory
|
Date: January 19, 2021
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Mar 2023 to Mar 2024